ScreenerHero

SRPTSarepta Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sarepta.com
18.79USD-4.76%Mkt Cap: 1.98B $P/E: —

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.98B $
Enterprise Value2.30B $
Revenue (TTM)1.97B $
Gross Profit1.36B $
Net Income (TTM)-713.41M $
Revenue/Share19.00 USD
Last Price18.79 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees835
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS8036071004
Valuation
P/E (Trailing)—
P/E (Forward)7.47
PEG-0.09
EV/EBITDA-131.41
EV/Revenue1.17
P/S1.03
P/B1.33
EPS (TTM)-1.53
EPS (Forward)2.57
52W Range
14.6939% of range25.32
52W High25.32 USD
52W Low14.69 USD
Profitability
Gross Margin61.81%
Oper. Margin13.03%
EBITDA Margin-0.89%
Profit Margin-32.45%
ROE-62.55%
ROA-21.30%
Growth
Revenue Growth-34.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-205.48M $
CapEx (TTM)109.85M $
FCF Margin1.12%
FCF Yield1.12%
Net Debt273.92M $
Net Debt/EBITDA-15.62
Balance Sheet
Debt/Equity0.91
Current Ratio4.42
Quick Ratio2.44
Book Value/Sh14.46 USD
Cash/Share7.465 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 12, 2012
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.09 USD
Upside (mean)+17.5%
Target Range5.000 USD – 38.00 USD
$5.000+17.5% to mean$38.00
# Analysts23
Ownership
Shares Out.105.63M
Float101.04M
Insiders4.93%
Institutions103.60%
Short Interest
Short Ratio8.6d
Short % Float31.28%
Short % Out.26.10%
Shares Short27.57M
Short (prev mo.)28.73M
Technical
SMA 5017.22 (+9.1%)
SMA 20019.05 (-1.3%)
Beta0.20
S&P 52W Chg18.16%
Avg Vol (30d)2.84M
Avg Vol (10d)2.64M
Technical Indicators
RSI (14)60.1
MACD0.5036
MACD Signal0.1722
MACD Hist.+0.3313
BB Upper19.66 USD
BB Middle16.88 USD
BB Lower14.10 USD
BB Width32.97%
ATR (14)0.9371 USD
Vol Ratio (20d)0.58x